Clinical Investigation iDesign System With 1.3-PRESBY Treatment and STAR S4 IR™ Excimer Laser System

Myopia Clinical Trial

Official title:

A Prospective Study to Evaluate the Feasibility of a New Treatment Algorithm to Increase Depth of Focus After Wavefront-guided LASIK Correction of Myopic Refractive Errors With the iDesign System and Star S4 IR™ Excimer Laser System

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02806726
• Other study ID #: STAR-116-TOPS
• Status: Terminated
• Phase: N/A
• Start date: July 13, 2016
• Est. completion date: November 9, 2017

Study information

• Verified date: February 2019
• Source: Abbott Medical Optics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective study to evaluate the feasibility of a new treatment algorithm to increase depth of focus after wavefront-guided LASIK correction of myopic refractive errors with the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System. The purpose of this study is to determine whether wavefront-guided LASIK correction of myopic refractive errors with CustomVue combined with iDesign 1.3-PRESBY (presbyT-LASIK) treatments mitigate the effects of presbyopia by increasing the depth of focus compared to iDesign CustomVue treatments.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 42
• Est. completion date: November 9, 2017
• Est. primary completion date: November 9, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

All criteria apply to each eye

1. Signed informed consent and Personal Health Information Protection Act authorization.

2. At least 45 years of age at enrollment (date informed consent signed).

3. The refractive error, based on the iDesign displayed refraction selected for treatment ("4.0 Rx calc" at 12.5 mm), must be myopia with or without astigmatism with sphere up to -6.00 D, and cylinder between 0.00 D and -5.00 D with a maximum spherical equivalent (SE) of -8.00 D.

4. Require an add power of +1.00 D or more during near testing at 40 cm.

5. Anticipated stromal bed thickness of at least 250 microns based on preoperative central corneal pachymetry minus the maximum ablation depth (as calculated by the iDesign system) plus the intended flap thickness.

6. Distance Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better.

7. Uncorrected Visual Acuity (UCVA) of 20/40 or worse.

8. Less than or equal to 0.75 D difference between cycloplegic and manifest refraction sphere.

9. A stable refractive error (based on a previous exam, medical records, lensometry, or prescription at least 12 months prior to the preoperative manifest refraction), as defined by a change of =1.00 D in MRSE.

10. Any eye with a history of contact lens wear within the last 4 weeks must demonstrate refractive stability according to the following:

1. Rigid contact lenses (toric or spherical) must be removed for at least 4 weeks and soft contact lenses (toric or spherical) for at least 2 weeks prior to the first refraction used to establish stability.

2. Two consecutive refractions and keratometric readings must be conducted at least 7 days apart.

3. Refractive stability is defined as a change of not more than 0.50 D in manifest refraction sphere and cylinder as well as mean keratometry between measurements.

4. If the subject/eye meets the refractive stability criteria, contact lens wear is not permitted prior to surgery.

11. Agreement between manifest refraction (adjusted for optical infinity) and iDesign System refraction chosen for treatment, as follows:

1. Spherical Equivalent: Magnitude of the difference is less than 0.625 D.

2. Cylinder: Magnitude of the difference is less than or equal to 0.5 D.

3. Cylinder Axis Tolerance: If either the manifest cylinder entered into the iDesign System or the iDesign cylinder selected for treatment is less than 0.5 D, there is no requirement for axis tolerance. When both cylinders have a magnitude of at least 0.5 D, the axis tolerance as determined by the iDesign system is linearly reduced from 15 (0.5 D) to 7.5 (7.0 D) based on the average magnitude of both cylinders. Note: If the axis tolerance is not in the calculated range, the iDesign system will produce a warning and this exam may not be used for treatment planning.

12. Willing and capable of complying with follow-up examinations for the duration of the study.

Exclusion Criteria:

1. Women who are pregnant, breast-feeding, intend to become pregnant, or are not using an adequate method of birth control [examples are any form of barrier contraception (such as condom or diaphragm with contraceptive cream/jelly), birth control pills, hormonal implant, IUD, abstinence or surgical sterilization (tubal ligation, hysterectomy or vasectomy)]. Note: Women who were pregnant or nursing may not be enrolled until 6 months after either delivery or have stopped nursing and there is documented refractive stability.

2. Concurrent use of systemic (including inhaled) medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment.

NOTE: The use of inhaled or systemic corticosteroids, whether chronic or acute, is deemed to adversely affect healing and subjects using such medications are specifically excluded from eligibility.

3. History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis.

NOTE: The presence of diabetes (either type 1 or 2), regardless of disease duration, severity, or control, will specifically exclude subjects from eligibility.

4. Subjects with a cardiac pacemaker, implanted defibrillator or other implanted electronic device.

5. History of prior intraocular or corneal surgery (including cataract extraction), active ophthalmic disease or abnormality (including, but not limited to, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization > 1 mm from limbus), retinal detachment/repair, clinically significant lens opacity, clinical evidence of trauma, corneal opacity within the central 9 mm and visible on topography, at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma.

NOTE: Subjects with open angle glaucoma, regardless of medication regimen or control, or an IOP greater than 21 mmHg at screening, are specifically excluded from eligibility.

6. Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal topography.

7. Known sensitivity or inappropriate responsiveness to any of the medications used in the postoperative course.

8. Desire to have monovision.

9. Intolerance to multifocal correction based on questionnaire responses to contact lens trial.

10. Participation in any other clinical study.

Related Conditions & MeSH terms

• Myopia
• Presbyopia

Intervention

Device:
• iDesign 1.3-PRESBY treatment
Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
• iDesign 1.3 treatment
Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.

Locations

Country	Name	City	State
Canada	University of Ottawa	Ottawa	Ontario
Canada	Crystal Clear Vision	Toronto	Ontario
Canada	Image Plus Laser Eye Center	Winnipeg	Manitoba

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Medical Optics

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 67 cm	Mean distance corrected intermediate visual acuity (DCIVA) for presbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control).	6 months
Secondary	Monocular Distance Corrected Near Visual Acuity (DCNVA) AT 40 cm	Mean distance corrected near visual acuity (DCNVA) for PresbyT-LASIK treatments (test) was compared to iDesign CustomVue treatments (control).	6 months